Transactions
2
Insider / NEOGENOMICS INC
Starrett Carolyn S
Director at NEOGENOMICS INC
- Company
- NEOGENOMICS INC
- Ticker
- NEO
- First filing on record
- June 25, 2026
- Latest trade on record
- June 23, 2026
- SEC filings
- EDGAR ↗
Starrett Carolyn S, Director at NEOGENOMICS INC, has disclosed 2 transactions in NEO since June 25, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed June 25, 2026, 2 days after the trade.
Open-market buys
0
Sales
0
Avg. disclosure lag
2.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Starrett Carolyn S reported 2 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 2 | 23,909 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| NEO | Other A | June 23, 2026 | June 25, 2026 | 2d | 14,125 | — | — | derivative | Form 4 ↗ | |
| NEO | Other A | June 23, 2026 | June 25, 2026 | 2d | 9,784 | — | — | derivative | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| June 25, 2026 | Form 4 | 0001628280-26-045501 | 2 | published | EDGAR ↗ |
Other insiders at NEOGENOMICS INC
- Stone Warren Pres & Chief Operating Officer 27 rows
- Olivo Alicia C EVP, GC & Business Development 19 rows
- Aunan Greg D Chief Accounting Officer 10 rows
- Sherman Jeffrey Scott Chief Financial Officer 7 rows
- Kenny John P. Director 6 rows
- TETRAULT LYNN A. Director 6 rows
- Zook Anthony P. Chief Executive Officer 5 rows
- Green Marjorie C Director 4 rows
- Gunn Neil Director 4 rows
- KANOVSKY STEPHEN M Director 4 rows
Everyone on file, with contracts and lobbying under the company's name: NEOGENOMICS INC.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 2 | June 25, 2026 | June 25, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.